Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
telbivudine
- Development stage
- Phase 4
- Lead developer
- Novartis
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules
- Administration
- Oral
01
Overview
Telbivudine is an oral antiviral drug classified as a nucleoside analogue and specifically a thymidine nucleoside analogue. It inhibits hepatitis B virus (HBV) replication by acting as a selective inhibitor of HBV DNA polymerase (reverse transcriptase), leading to chain termination during viral DNA synthesis. Telbivudine is used for the treatment of chronic hepatitis B infection in adults and adolescents with evidence of active viral replication and either persistent elevations in serum aminotransferases or histologically active disease. While it can reduce HBV levels, it does not cure hepatitis B or prevent its complications such as cirrhosis or liver cancer, nor does it prevent transmission to others[1][4][5][6]. Telbivudine was developed by Novartis and marketed under the brand name Tyzeka but has been discontinued in some markets including the United States[1].
- Brand names
- Tyzeka
- Other names
- 替比夫定Epavudine
02
Targets
HBV Pol (Hepatitis B virus polymerase)
Beyond the preview
Go deeper on telbivudine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on telbivudine.